Pfizer has asked a federal court to let it intervene in a high-profile case that has seen U.S. drug regulators try to slow-walk disclosure of data on Pfizer’s COVID-19 vaccine.
Pfizer says it supports disclosing the data but wants to ensure that information exempt from disclosure under the Freedom of Information Act (FOIA) is not “disclosed inappropriately.”
Public Health and Medical Professionals for Transparency filed a lawsuit against the Food and Drug Administration (FDA) last year after the agency, responding to a FOIA request, claiming it would take 20 years to produce the data on the vaccine.
The FDA later asked a judge to give it 75 years, but the judge rejected the request and ordered the regulator to produce 55,000 pages a month, which would give it about eight months to fully disclose the records.
About two weeks after the order, on Jan. 21, lawyers representing Pfizer asked U.S. District Judge Mark Pittman, a Trump nominee overseeing the case, to allow the company to intervene.
Pfizer was not aware of the case until executives read news reports about it last month and now wants to help FDA staffers review the documents in question to ensure proper redactions are made, according to the new filing.
In light of the FDA’s objections to the sped-up timeframe, Pfizer “seeks leave to intervene in this action for the limited purpose of ensuring that information exempt from disclosure under FOIA is adequately protected as FDA complies with this Court’s order,” the memorandum supporting the motion for leave to intervene stated.
Government officials told the court that they want Pfizer’s help “due to the unprecedented speed with which the Court has ordered FDA to process the records at issue.”
“FDA anticipates that coordination with Pfizer to obtain the company’s views as to which portions of the records are subject to Exemption 4, the Trade Secrets Act, 18 U.S.C. § 1905, or other statutory protections will be a necessary component of the agency’s endeavors to meet the extraordinary exigencies of this case,” Department of Justice lawyers said in a response to Pfizer’s motion.
Plaintiffs, though, asked Pittman to reject Pfizer’s bid.
“Even though the FDA has more than sufficient resources to expeditiously produce the requested documents, and the agency has repeatedly stated its commitment to protecting Pfizer’s interests, Pfizer could still assist the FDA with expediting release of the requested documents. Pfizer, however, provides no reason why it needs to intervene in this matter to render that purported assistance. Nor can Plaintiff discern why Pfizer needs to intervene in this matter to assist the FDA with expediting release of the requested documents—it can render this assistance without intervening,” Public Health and Medical Professionals for Transparency said in a brief.
The judge, the group said, should ask Pfizer to clarify how intervening would help quicken the document production.
Additionally, Pfizer lawyers told plaintiffs that while the company does not at present plan to challenge the court’s production order, they would not rule out challenging the order at a later time.
“Pfizer does not presently intend to move the Court to reconsider its January 6, 2022 order, but Pfizer is not in a position at this time to waive its ability to do so if circumstances change such that there is good cause at a later time to do so,” Daniel Tobey, one of Pfizer’s lawyers, said in a statement to the court.
Plaintiffs are concerned that Pfizer’s involvement will lead to the FDA renewing effort to delay production of the vaccine data.
Pittman is due to hear arguments for and against Pfizer’s proposed intervention on Jan. 28 in federal court in Fort Worth, Texas.
Regulators granted emergency use authorization to Pfizer’s vaccine in December 2020, alleging at the time that it was highly effective in preventing infection and severe disease.
The vaccine has since been proven to provide little protection against infection and its effectiveness against severe illness has dropped. Some side effects linked to the vaccine, meanwhile, were detected post-authorization, including heart inflammation and severe allergic reactions.
FDA and other U.S. officials continue to recommend virtually all Americans should get the jab and recently cleared booster doses for individuals 12 and older, while children as young as 5 can get Pfizer’s primary series.
Source: www.theepochtimes.com/pfizer-moves-to-intervene-in-high-profile-case-dealing-with-covid-19-vaccine-safety-data_4238676.html